Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP - Report - MDSpire

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP

  • By

  • Przemysław R. Kac

  • Katheryn A. Q. Cousins

  • Alicja Szadziewska

  • Leslie M. Shaw

  • Michael Turton

  • Vivianna M. Van Deerlin

  • Peter Harrison

  • Henrik Zetterberg

  • David A. Wolk

  • Corey T. McMillan

  • Douglas Galasko

  • Jörg Hanrieder

  • Edward B. Lee

  • Hlin Kvartsberg

  • David J. Irwin

  • Kaj Blennow

  • June 24, 2026

  • 0 min

Share

Clinical Report: Tau368 Enhances Diagnostic Precision of p-tau for FTLD-tau

Overview

The study evaluates the diagnostic utility of tau368 in distinguishing FTLD-tau from FTLD-TDP. It highlights the limitations of current biomarkers.

Background

Tauopathies, including FTLD-tau, are neurodegenerative diseases characterized by tau protein abnormalities. Accurate biomarkers are essential for clinical trials and diagnosis, especially given the heterogeneity of FTLD. Current fluid biomarkers lack specificity for FTLD-tau.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

  • Tau368 targets specific tau fragments.
  • Current biomarkers for FTLD-tau are insufficient due to the disease's heterogeneity.
  • Clinical diagnosis alone is inadequate for predicting FTLD pathology.
  • MTBR-tau fragments have shown potential in association with tau pathology.

Clinical Implications

The identification of tau368 as a potential biomarker may facilitate more accurate diagnoses of FTLD-tau.

Conclusion

The study suggests that tau368 could serve as a tool in differentiating FTLD-tau from FTLD-TDP.

Related Resources & Content

  1. Acta Neuropathologica, 2023 -- CSF p-tau205: An Indicator of Tau Pathology in Alzheimer’s Disease
  2. Acta Neuropathologica, 2021 -- Plasma p-tau231: An Emerging Biomarker for Early Detection of Alzheimer’s Disease Pathology
  3. conexiant -- Plasma pTau217 Cutoffs for Clinical Use
  4. Acta Neuropathologica, 2025 -- Early tau multimers capable of seeding are linked to transcriptional profiles specific to different cell types
  5. Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group | Communications Medicine
  6. An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration | Nature Medicine
  7. Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group | Communications Medicine
  8. An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration | Nature Medicine
  9. https://gupea.ub.gu.se/server/api/core/bitstreams/da64fb09-14f7-4658-b89f-f5bf8aefee39/content

Original Source(s)

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP

  • by Przemysław R. Kac, Katheryn A. Q. Cousins, Alicja Szadziewska, Leslie M. Shaw, Michael Turton, Vivianna M. Van Deerlin, Peter Harrison, Henrik Zetterberg, David A. Wolk, Corey T. McMillan, Douglas Galasko, Jörg Hanrieder, Edward B. Lee, Hlin Kvartsberg, David J. Irwin, Kaj Blennow

  • June 24, 2026

Related Content

Smartphone-based detection of subtle memory decline in prodromal Alzheimer’s disease

Alternative splicing-based therapeutics for neurodegenerative diseases: a dual-database bibliometric and NLP-driven analysis (2000–2025)

An intelligent gradient-guided hybrid inpainting framework for brain MRI reconstruction and Alzheimer's disease classification in connected healthcare systems